SHPH•benzinga•
Shuttle Pharmaceuticals Announces Filing Of Key Provisional Patent Application With The United States Patent And Trademark Office Entitled PSMA-Targeted PARP Inhibitor Conjugates for Precision Cancer Therapy
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 10, 2025 by benzinga